针对性心率控制与兰迪洛尔在血液动力学不稳定,非手术重症监护室患者:一项比较研究
Lyuboslav Katov1, Jessica Gierak1, Yannick Teumer1
1Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Medicina (Kaunas, Lithuania)
|September 27, 2025
概括
兰迪洛尔在危急病患者 (CIP) 中有效控制了心率 (HR),而不会对血压 (BP) 产生负面影响. 这种超短效β-阻塞剂为在重症监护室 (ICU) 治疗心律失常提供了一种安全的替代方案.
科学领域:
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在重症患者 (CIP) 中,心房动 (AF) 与不良结果和重症监护室 (ICU) 死亡率的增加相关.
- 由于并发症,在CIP中偏好控制AF的速率,但传统的β-阻断剂可以破坏血液动力学稳定.
- 兰迪奥洛尔是一种超短效β抑制剂,由于其心脏选择性和对血压的影响最小,因此具有潜在的优势.
研究的目的:
- 评估兰地作为心率控制 (HR) 的附加疗法的疗效和可行性,在血液动力学不稳定的急性病患者 (CIP) 中.
- 评估兰迪诺洛对心率 (HR) 和平均动脉压 (MAP) 的影响,与重症监护室 (ICU) 标准治疗相比.
主要方法:
- 在血动力学不稳定的ICU患者中,前性研究比较兰迪诺洛补充疗法 (L组,n=10) 与标准疗法 (NL组,n=41).
- 主要终点:HR减少,同时保持MAP>65 mmHg.
- 在3小时的观察期间收集了血液动力学状态,HR和MAP的数据.
主要成果:
- 兰地和标准治疗组之间没有观察到血压 (BP) 的显著差异.
- 主要复合终点在两组中都以可比率实现 (p=0.525).
- 与标准治疗相比,兰迪洛洛治疗导致心率 (HR) 显著降低 (25.3%与21.9%,p < 0.001).
结论:
- 兰迪洛尔在危急病患者 (CIP) 中有效控制了心率 (HR),而不会影响血压 (BP) 的稳定性.
- 与标准治疗相比,兰迪洛尔在这个ICU人群中显示出优异的HR降低.
- 兰迪洛尔代表了一个可行的和有效的选择,用于心率 (HR) 管理在血液动力学不稳定的ICU患者与心动节律失常.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Cardiopulmonary Resuscitation IV: Pharmacological Management
665
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
665
Pulse rhythm
1.3K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.3K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure Drugs: β-Blockers
771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771


